Arbutus Biopharma Past Earnings Performance
Past criteria checks 0/6
Arbutus Biopharma has been growing earnings at an average annual rate of 11.2%, while the Biotechs industry saw earnings growing at 15.3% annually. Revenues have been growing at an average rate of 38.2% per year.
Key information
11.2%
Earnings growth rate
33.7%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 38.2% |
Return on equity | -68.7% |
Net Margin | -401.6% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation
Feb 10Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 03Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week
Nov 09Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio
Oct 24We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow
Apr 26Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher
Nov 11We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth
Oct 28Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'
Sep 12Arbutus stock rises on US patent linked to hepatitis B therapy AB-729
Aug 30Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts
Aug 06Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial
Jul 20Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release
Jun 29We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth
Jun 15Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic
May 11Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues
Mar 08Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest
Mar 07Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?
Dec 17Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans
Dec 14Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment
Nov 20Arbutus Biopharma: A First Assessment
Sep 15We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate
Sep 11Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment
Jun 29Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans
May 21Arbutus Bio slips 4% as Q1 revenue trails consensus
May 05What You Need To Know About Arbutus Biopharma Corporation's (NASDAQ:ABUS) Investor Composition
Mar 12We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth
Feb 02Arbutus Biopharma's (NASDAQ:ABUS) Stock Price Has Reduced 29% In The Past Three Years
Jan 07Arbutus Biopharma (ABUS) Investor Presentation - Slideshow
Dec 17What Is The Ownership Structure Like For Arbutus Biopharma Corporation (NASDAQ:ABUS)?
Dec 12Revenue & Expenses BreakdownBeta
How Arbutus Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 18 | -73 | 22 | 0 |
30 Sep 23 | 22 | -75 | 22 | 0 |
30 Jun 23 | 24 | -73 | 19 | 0 |
31 Mar 23 | 33 | -70 | 18 | 0 |
31 Dec 22 | 39 | -69 | 18 | 0 |
30 Sep 22 | 36 | -69 | 18 | 0 |
30 Jun 22 | 33 | -76 | 19 | 0 |
31 Mar 22 | 21 | -85 | 18 | 0 |
31 Dec 21 | 11 | -88 | 17 | 0 |
30 Sep 21 | 10 | -87 | 16 | 0 |
30 Jun 21 | 8 | -84 | 16 | 0 |
31 Mar 21 | 8 | -79 | 15 | 0 |
31 Dec 20 | 7 | -76 | 15 | 0 |
30 Sep 20 | 6 | -83 | 13 | 0 |
30 Jun 20 | 8 | -147 | 10 | 0 |
31 Mar 20 | 7 | -156 | 13 | 0 |
31 Dec 19 | 6 | -165 | 14 | 0 |
30 Sep 19 | 6 | -158 | 18 | 0 |
30 Jun 19 | 5 | -100 | 20 | 0 |
31 Mar 19 | 5 | -73 | 17 | 0 |
31 Dec 18 | 6 | -67 | 16 | 0 |
30 Sep 18 | 7 | -83 | 14 | 0 |
30 Jun 18 | 12 | -68 | 15 | 0 |
31 Mar 18 | 12 | -86 | 15 | 0 |
31 Dec 17 | 11 | -85 | 16 | 0 |
30 Sep 17 | 8 | -267 | 16 | 0 |
30 Jun 17 | 2 | -275 | 14 | 0 |
31 Mar 17 | 1 | -387 | 15 | 0 |
31 Dec 16 | 1 | -384 | 13 | 0 |
30 Sep 16 | 14 | -171 | 14 | 0 |
30 Jun 16 | 18 | -180 | 12 | 0 |
31 Mar 16 | 21 | -65 | 14 | 0 |
31 Dec 15 | 23 | -63 | 26 | 0 |
30 Sep 15 | 17 | -62 | 13 | 0 |
30 Jun 15 | 17 | -42 | 15 | 0 |
31 Mar 15 | 15 | -33 | 9 | 0 |
31 Dec 14 | 15 | -39 | 9 | 0 |
30 Sep 14 | 18 | -35 | 8 | 0 |
30 Jun 14 | 17 | -33 | 8 | 0 |
31 Mar 14 | 18 | -30 | 7 | 0 |
31 Dec 13 | 15 | -14 | 6 | 0 |
30 Sep 13 | 12 | 26 | 5 | 0 |
30 Jun 13 | 12 | 29 | 6 | 0 |
31 Mar 13 | 13 | 30 | 7 | 0 |
Quality Earnings: ABUS is currently unprofitable.
Growing Profit Margin: ABUS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ABUS is unprofitable, but has reduced losses over the past 5 years at a rate of 11.2% per year.
Accelerating Growth: Unable to compare ABUS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ABUS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: ABUS has a negative Return on Equity (-68.71%), as it is currently unprofitable.